Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Partners with Persistent on Chromatography Interoperability

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has inked a collaboration with Persistent Systems aimed at promoting open systems for chromatography data systems.

The firm said that as part of the agreement it has joined DriverCentral.net, a device driver portal for analytical instrument driver purchases that is led by Persistent.

Agilent said that it will collaborate with Persistent in three primary ways by transferring many of its non-Agilent instrument drivers to Persistent for further development and support; by providing documentation on its RC.NET technology to convert legacy drivers to the new standard and develop new drivers based on RC.NET; and by joining DriverCentral.net to make its own analytical instrument drivers available through the portal.

"Agilent supports open systems and open access to the RC.NET standard so that customers can choose instrumentation from other vendors, when necessary, while still maintaining their Agilent data system," Bruce von Herrmann, VP and GM of Agilent's software and informatics business unit, said in a statement. "Additionally, with this partnership we strengthen our commitment to open architecture and open systems, the foundation of our OpenLAB brand."

Financial and further terms of the agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.